All In Biotech

Drug Trial Radar · NCT04618211

Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

A Phase II, Double-blind, Placebo-controlled, Randomized, Cross-over, Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema Due to C1-inhibitor Deficiency Type I and II

Last checked: Nov 19, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

74

Actual

Start

Feb 3, 2021

Primary completion

Sep 23, 2022

Study completion Mar 1, 2023

Sponsor

Lead sponsor
Pharvaris Netherlands B.V.Industry
Sponsor type
Industry
First posted
Nov 5, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the efficacy of orally administered deucrictibant for the acute treatment of attacks in patients with hereditary angioedema (HAE). Eligible subjects are randomized to one of three single doses of deucrictibant and placebo. The study will compare symptom relief (skin pain, skin swelling, abdominal pain) during HAE attacks and safety of each dose of deucrictibant with placebo.

Conditions

  • Hereditary Angioedema
  • Hereditary Angioedema Type I
  • Hereditary Angioedema Type II
  • Hereditary Angioedema Types I and II
  • Hereditary Angioedema Attack
  • Hereditary Angioedema With C1 Esterase Inhibitor Deficiency
  • Hereditary Angioedema - Type 1
  • Hereditary Angioedema - Type 2
  • C1 Esterase Inhibitor Deficiency
  • C1 Inhibitor Deficiency

Interventions

  • DeucrictibantDrug

    deucrictibant soft capsules for oral use

  • PlaceboDrug

    Matching placebo capsules for oral use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change of the 3-symptom Composite Visual Analogue Scale (VAS-3) Score From Pre-treatment to 4 Hours Post-treatmentTime frame: Assessed from pre-treatment to 4 hours post-treatment

Locations

36 sites in 13 countries. Site status is shown where the registry gives one.

  • Study site

    Birmingham, Alabama

  • Study site

    Paradise Valley, Arizona

  • Study site

    San Diego, California

  • Study site

    Santa Monica, California

  • Study site

    Walnut Creek, California

  • Study site

    Chevy Chase, Maryland

  • Study site

    St Louis, Missouri

  • Study site

    Hershey, Pennsylvania

  • Study site

    Sofia, Bulgaria

  • Study site

    Edmonton, Alberta, Canada

  • Study site

    Ottawa, Ontario, Canada

  • Study site

    Toronto, Ontario, Canada

  • Study site

    Montreal, Quebec, Canada

  • Study site

    Québec, Quebec, Canada

  • Study site

    Brno, Czechia

  • Study site

    Hradec Králové, Czechia

  • Study site

    Grenoble, France

  • Study site

    Montpellier, France

  • Study site

    Paris, France

  • Study site

    Berlin, Germany

  • Study site

    Dresden, Germany

  • Study site

    Frankfurt, Germany

  • Study site

    Mainz, Germany

  • Study site

    Ulm, Germany

  • Study site

    Budapest, Hungary

  • Study site

    Ashkelon, Israel

  • Study site

    Haifa, Israel

  • Study site

    Tel Aviv, Israel

  • Study site

    Monserrato, Italy

  • Study site

    Naples, Italy

  • Study site

    Amsterdam, Netherlands

  • Study site

    Krakow, Poland

  • Study site

    Barcelona, Spain

  • Study site

    Madrid, Spain

  • Study site

    Brighton, United Kingdom

  • Study site

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.